Review



primary antibodies for col1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Proteintech primary antibodies for col1
    Primary Antibodies For Col1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 671 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies for col1/product/Proteintech
    Average 96 stars, based on 671 article reviews
    primary antibodies for col1 - by Bioz Stars, 2026-02
    96/100 stars

    Images



    Similar Products

    96
    Proteintech primary antibodies for col1
    Primary Antibodies For Col1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies for col1/product/Proteintech
    Average 96 stars, based on 1 article reviews
    primary antibodies for col1 - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    90
    Cell Signaling Technology Inc col1 primary antibody
    Col1 Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/col1 primary antibody/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    col1 primary antibody - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Proteintech primary antibodies against col1
    Primary Antibodies Against Col1, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against col1/product/Proteintech
    Average 90 stars, based on 1 article reviews
    primary antibodies against col1 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Novotec Medical GmbH primary antibody against col1 20121
    Primary Antibody Against Col1 20121, supplied by Novotec Medical GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody against col1 20121/product/Novotec Medical GmbH
    Average 90 stars, based on 1 article reviews
    primary antibody against col1 20121 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Novotec Medical GmbH primary antibody against col1 (1:1000 diluted; rrid: ab_2891017, 20121
    The effect of progesterone (P4; 10 − 7 M) or 17β-estradiol (E2; 10 − 9 M) on mRNA expression of <t>collagen</t> <t>type</t> <t>1</t> alpha chain 1 ( COL1A1) ( A ), collagen type 3 alpha chain 1 ( COL3A1) ( B ), matrix metalloproteases (MMP): MMP-1 ( C ), MMP-2 ( D ), MMP-3 ( E ), MMP-9 ( F ), and MMP-13 ( G ), and tissue inhibitors of matrix metalloproteases (TIMPs): TIMP-1 ( H ) and TIMP-2 ( I ) in equine endometrial fibroblasts. Data were analyzed by Student’s t-test and expressed as mean ± SEM. Asterisks designate statistical differences between treatments (* p < 0.05; ** p < 0.01; *** p < 0.001; **** P < 0.0001).
    Primary Antibody Against Col1 (1:1000 Diluted; Rrid: Ab 2891017, 20121, supplied by Novotec Medical GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody against col1 (1:1000 diluted; rrid: ab_2891017, 20121/product/Novotec Medical GmbH
    Average 90 stars, based on 1 article reviews
    primary antibody against col1 (1:1000 diluted; rrid: ab_2891017, 20121 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Abmart Inc primary antibody col1
    In vitro and in vivo biocompatibility and osseointegration evaluation of the functionalized titanium screws. A,B) Representative western blot images of the expression of osteogenesis‐related proteins and C,D) corresponding quantitative analyses ( n = 3). E) Immunofluorescence images of <t>RUNX2</t> and COL1 staining of MEFs in different groups. F) Schematic diagram of the osseointegration and biocompatibility test of functionalized screws in an uninfected bone defect model. G) The implantation process of functionalized screws in rabbit tibial plateau. H) The micro‐CT 3D reconstructed images and I) bone tissue volume/total tissue volume (BV/TV) analysis from micro‐CT results of the newly formed bone surrounding the screws after 56 days of implantation ( n = 3). J) The methylene blue‐basic magenta staining and corresponding K) bone‐implant contact (BIC) ratio analysis of the non‐decalcified bone sections for osseointegration assay ( n = 3). Green arrows indicate gaps between the screw and bone tissue. Blue arrows indicate bone‐implant contact areas. In I,J), The data are shown as the means ± SDs, * p < 0.05, ** p < 0.01, *** p < 0.001.
    Primary Antibody Col1, supplied by Abmart Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody col1/product/Abmart Inc
    Average 90 stars, based on 1 article reviews
    primary antibody col1 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc primary antibodies against col1
    WAC was up‐regulated during the osteogenic differentiation of MSCs. a) ARS Staining and quantification throughout MSC osteogenic differentiation; b) ALP Staining and quantification during the progression of MSC osteogenesis; c) Immunofluorescence Staining for <t>COL1</t> (red) during osteogenic induction. Quantification is presented in the right panel (Scale bar = 50 µm); d) Relative mRNA levels of WAC assessed by qRT‐PCR at different time points during MSC osteogenesis; e) Protein levels of WAC and osteogenic markers (RUNX2, Osterix, OCN) during MSC osteogenic differentiation; f) Pearson correlation analysis depicting the relationship between WAC expression and quantification of RUNX2, Osterix, and OCN levels during MSC osteogenic differentiation; g) qRT–PCR and Western blotting to detect WAC mRNA and protein levels in bone marrow MSCs from nonosteoporotic patients and patients with osteoporosis; h) HE staining and immunohistochemical staining for WAC in the femurs of SAMR1 mice and SAMP6 mice (Scale bar = 100 µm). All data are presented as the means ± SD, n = 6 per group in (a, b, c), n = 5 in (g), n = 9 in (d, e, g), n = 12 in (f). Statistical differences were determined using Student's t ‐test or ANOVA. ** p < 0.01 and *** p < 0.001.
    Primary Antibodies Against Col1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against col1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    primary antibodies against col1 - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    90
    Proteintech primary antibodies against ocn and col1
    WAC was up‐regulated during the osteogenic differentiation of MSCs. a) ARS Staining and quantification throughout MSC osteogenic differentiation; b) ALP Staining and quantification during the progression of MSC osteogenesis; c) Immunofluorescence Staining for <t>COL1</t> (red) during osteogenic induction. Quantification is presented in the right panel (Scale bar = 50 µm); d) Relative mRNA levels of WAC assessed by qRT‐PCR at different time points during MSC osteogenesis; e) Protein levels of WAC and osteogenic markers (RUNX2, Osterix, OCN) during MSC osteogenic differentiation; f) Pearson correlation analysis depicting the relationship between WAC expression and quantification of RUNX2, Osterix, and OCN levels during MSC osteogenic differentiation; g) qRT–PCR and Western blotting to detect WAC mRNA and protein levels in bone marrow MSCs from nonosteoporotic patients and patients with osteoporosis; h) HE staining and immunohistochemical staining for WAC in the femurs of SAMR1 mice and SAMP6 mice (Scale bar = 100 µm). All data are presented as the means ± SD, n = 6 per group in (a, b, c), n = 5 in (g), n = 9 in (d, e, g), n = 12 in (f). Statistical differences were determined using Student's t ‐test or ANOVA. ** p < 0.01 and *** p < 0.001.
    Primary Antibodies Against Ocn And Col1, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against ocn and col1/product/Proteintech
    Average 90 stars, based on 1 article reviews
    primary antibodies against ocn and col1 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology fluorescence-conjugated primary antibodies anti-col1
    WAC was up‐regulated during the osteogenic differentiation of MSCs. a) ARS Staining and quantification throughout MSC osteogenic differentiation; b) ALP Staining and quantification during the progression of MSC osteogenesis; c) Immunofluorescence Staining for <t>COL1</t> (red) during osteogenic induction. Quantification is presented in the right panel (Scale bar = 50 µm); d) Relative mRNA levels of WAC assessed by qRT‐PCR at different time points during MSC osteogenesis; e) Protein levels of WAC and osteogenic markers (RUNX2, Osterix, OCN) during MSC osteogenic differentiation; f) Pearson correlation analysis depicting the relationship between WAC expression and quantification of RUNX2, Osterix, and OCN levels during MSC osteogenic differentiation; g) qRT–PCR and Western blotting to detect WAC mRNA and protein levels in bone marrow MSCs from nonosteoporotic patients and patients with osteoporosis; h) HE staining and immunohistochemical staining for WAC in the femurs of SAMR1 mice and SAMP6 mice (Scale bar = 100 µm). All data are presented as the means ± SD, n = 6 per group in (a, b, c), n = 5 in (g), n = 9 in (d, e, g), n = 12 in (f). Statistical differences were determined using Student's t ‐test or ANOVA. ** p < 0.01 and *** p < 0.001.
    Fluorescence Conjugated Primary Antibodies Anti Col1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluorescence-conjugated primary antibodies anti-col1/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    fluorescence-conjugated primary antibodies anti-col1 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Affinity Biosciences type i collagen (col1) primary antibody
    WAC was up‐regulated during the osteogenic differentiation of MSCs. a) ARS Staining and quantification throughout MSC osteogenic differentiation; b) ALP Staining and quantification during the progression of MSC osteogenesis; c) Immunofluorescence Staining for <t>COL1</t> (red) during osteogenic induction. Quantification is presented in the right panel (Scale bar = 50 µm); d) Relative mRNA levels of WAC assessed by qRT‐PCR at different time points during MSC osteogenesis; e) Protein levels of WAC and osteogenic markers (RUNX2, Osterix, OCN) during MSC osteogenic differentiation; f) Pearson correlation analysis depicting the relationship between WAC expression and quantification of RUNX2, Osterix, and OCN levels during MSC osteogenic differentiation; g) qRT–PCR and Western blotting to detect WAC mRNA and protein levels in bone marrow MSCs from nonosteoporotic patients and patients with osteoporosis; h) HE staining and immunohistochemical staining for WAC in the femurs of SAMR1 mice and SAMP6 mice (Scale bar = 100 µm). All data are presented as the means ± SD, n = 6 per group in (a, b, c), n = 5 in (g), n = 9 in (d, e, g), n = 12 in (f). Statistical differences were determined using Student's t ‐test or ANOVA. ** p < 0.01 and *** p < 0.001.
    Type I Collagen (Col1) Primary Antibody, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/type i collagen (col1) primary antibody/product/Affinity Biosciences
    Average 90 stars, based on 1 article reviews
    type i collagen (col1) primary antibody - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    The effect of progesterone (P4; 10 − 7 M) or 17β-estradiol (E2; 10 − 9 M) on mRNA expression of collagen type 1 alpha chain 1 ( COL1A1) ( A ), collagen type 3 alpha chain 1 ( COL3A1) ( B ), matrix metalloproteases (MMP): MMP-1 ( C ), MMP-2 ( D ), MMP-3 ( E ), MMP-9 ( F ), and MMP-13 ( G ), and tissue inhibitors of matrix metalloproteases (TIMPs): TIMP-1 ( H ) and TIMP-2 ( I ) in equine endometrial fibroblasts. Data were analyzed by Student’s t-test and expressed as mean ± SEM. Asterisks designate statistical differences between treatments (* p < 0.05; ** p < 0.01; *** p < 0.001; **** P < 0.0001).

    Journal: Scientific Reports

    Article Title: Ovarian steroids modulate mRNA expression of ECM associated genes and collagen deposition induced by TGF β1 in equine endometrium in vitro

    doi: 10.1038/s41598-024-84250-1

    Figure Lengend Snippet: The effect of progesterone (P4; 10 − 7 M) or 17β-estradiol (E2; 10 − 9 M) on mRNA expression of collagen type 1 alpha chain 1 ( COL1A1) ( A ), collagen type 3 alpha chain 1 ( COL3A1) ( B ), matrix metalloproteases (MMP): MMP-1 ( C ), MMP-2 ( D ), MMP-3 ( E ), MMP-9 ( F ), and MMP-13 ( G ), and tissue inhibitors of matrix metalloproteases (TIMPs): TIMP-1 ( H ) and TIMP-2 ( I ) in equine endometrial fibroblasts. Data were analyzed by Student’s t-test and expressed as mean ± SEM. Asterisks designate statistical differences between treatments (* p < 0.05; ** p < 0.01; *** p < 0.001; **** P < 0.0001).

    Article Snippet: The primary antibody against COL1 (1:1000 diluted; RRID: AB_2891017, 20121, Novotec, Lyon, France) was incubated overnight at 4ºC, and the secondary antibody horseradish peroxidase (HRP)-conjugated anti-rabbit (1:20,000; RRID: AB_2617138; P0448, DakoCytomation, Carpinteria, CA, USA) was incubated during 1.5 h at room temperature.

    Techniques: Expressing

    Relative collagen type I alpha chain 2 ( COL1A2 ) mRNA expression of equine endometrial explants obtained from mares in the follicular phase (FP; n = 5) and treated for 24 ( A ) or 48 h ( B ) with medium alone (control), transforming growth factor β1 (TGF-β1; 10 ng/mL), TGF-β1 (10ng/mL) + 17β-estradiol (E2; 10 − 9 M) or E2 alone (10 − 9 M). Results were analyzed by one-way analysis of variance (ANOVA), followed by a Tukey’s multiple comparisons test and considered significant at p < 0.05 and shown as mean ± SEM. Asterisks represent significant differences relative to the respective control and asterisks above lines designate differences between treatments (* p < 0.05; ** p < 0.01; **** P < 0.0001).

    Journal: Scientific Reports

    Article Title: Ovarian steroids modulate mRNA expression of ECM associated genes and collagen deposition induced by TGF β1 in equine endometrium in vitro

    doi: 10.1038/s41598-024-84250-1

    Figure Lengend Snippet: Relative collagen type I alpha chain 2 ( COL1A2 ) mRNA expression of equine endometrial explants obtained from mares in the follicular phase (FP; n = 5) and treated for 24 ( A ) or 48 h ( B ) with medium alone (control), transforming growth factor β1 (TGF-β1; 10 ng/mL), TGF-β1 (10ng/mL) + 17β-estradiol (E2; 10 − 9 M) or E2 alone (10 − 9 M). Results were analyzed by one-way analysis of variance (ANOVA), followed by a Tukey’s multiple comparisons test and considered significant at p < 0.05 and shown as mean ± SEM. Asterisks represent significant differences relative to the respective control and asterisks above lines designate differences between treatments (* p < 0.05; ** p < 0.01; **** P < 0.0001).

    Article Snippet: The primary antibody against COL1 (1:1000 diluted; RRID: AB_2891017, 20121, Novotec, Lyon, France) was incubated overnight at 4ºC, and the secondary antibody horseradish peroxidase (HRP)-conjugated anti-rabbit (1:20,000; RRID: AB_2617138; P0448, DakoCytomation, Carpinteria, CA, USA) was incubated during 1.5 h at room temperature.

    Techniques: Expressing, Control

    Relative collagen type I (COL1) protein abundance in equine endometrial explants obtained from mares in the follicular phase (FP; n = 5) and treated for 24 ( A ) or 48 h ( B ) with medium alone (control), transforming growth factor β1 (TGF-β1; 10 ng/mL), TGF-β1 (10ng/mL) + 17β-estradiol (E2; 10 − 9 M) or E2 (10 − 9 M), respectively. Results were analyzed by one-way analysis of variance (ANOVA), followed by a Tukey’s multiple comparisons test and considered significant at p < 0.05 and shown as mean ± SEM. Asterisks represent significant differences relative to the respective control and asterisks above lines designate differences between treatments (* p < 0.05; ** p < 0.01; *** P < 0.001).

    Journal: Scientific Reports

    Article Title: Ovarian steroids modulate mRNA expression of ECM associated genes and collagen deposition induced by TGF β1 in equine endometrium in vitro

    doi: 10.1038/s41598-024-84250-1

    Figure Lengend Snippet: Relative collagen type I (COL1) protein abundance in equine endometrial explants obtained from mares in the follicular phase (FP; n = 5) and treated for 24 ( A ) or 48 h ( B ) with medium alone (control), transforming growth factor β1 (TGF-β1; 10 ng/mL), TGF-β1 (10ng/mL) + 17β-estradiol (E2; 10 − 9 M) or E2 (10 − 9 M), respectively. Results were analyzed by one-way analysis of variance (ANOVA), followed by a Tukey’s multiple comparisons test and considered significant at p < 0.05 and shown as mean ± SEM. Asterisks represent significant differences relative to the respective control and asterisks above lines designate differences between treatments (* p < 0.05; ** p < 0.01; *** P < 0.001).

    Article Snippet: The primary antibody against COL1 (1:1000 diluted; RRID: AB_2891017, 20121, Novotec, Lyon, France) was incubated overnight at 4ºC, and the secondary antibody horseradish peroxidase (HRP)-conjugated anti-rabbit (1:20,000; RRID: AB_2617138; P0448, DakoCytomation, Carpinteria, CA, USA) was incubated during 1.5 h at room temperature.

    Techniques: Control

    Relative collagen type I alpha chain 2 ( COL1A2 ) mRNA expression in equine endometrial explants obtained from mares in the mid-luteal phase (MLP; n = 5), and treated for 24 ( A ) or 48 h ( B ) with medium alone (control), transforming growth factor β1 (TGF-β1; 10 ng/mL), TGF-β1 (10ng/mL) + progesterone (P4; 10 − 7 M) or P4 alone (10 − 7 M). Results were analyzed by one-way analysis of variance (ANOVA), followed by a Tukey’s multiple comparisons test and considered significant at p < 0.05 and shown as mean ± SEM. Asterisks represent significant differences relative to the respective control and asterisks above lines designate differences between treatments (* p < 0.05; ** p < 0.01; *** P < 0.001).

    Journal: Scientific Reports

    Article Title: Ovarian steroids modulate mRNA expression of ECM associated genes and collagen deposition induced by TGF β1 in equine endometrium in vitro

    doi: 10.1038/s41598-024-84250-1

    Figure Lengend Snippet: Relative collagen type I alpha chain 2 ( COL1A2 ) mRNA expression in equine endometrial explants obtained from mares in the mid-luteal phase (MLP; n = 5), and treated for 24 ( A ) or 48 h ( B ) with medium alone (control), transforming growth factor β1 (TGF-β1; 10 ng/mL), TGF-β1 (10ng/mL) + progesterone (P4; 10 − 7 M) or P4 alone (10 − 7 M). Results were analyzed by one-way analysis of variance (ANOVA), followed by a Tukey’s multiple comparisons test and considered significant at p < 0.05 and shown as mean ± SEM. Asterisks represent significant differences relative to the respective control and asterisks above lines designate differences between treatments (* p < 0.05; ** p < 0.01; *** P < 0.001).

    Article Snippet: The primary antibody against COL1 (1:1000 diluted; RRID: AB_2891017, 20121, Novotec, Lyon, France) was incubated overnight at 4ºC, and the secondary antibody horseradish peroxidase (HRP)-conjugated anti-rabbit (1:20,000; RRID: AB_2617138; P0448, DakoCytomation, Carpinteria, CA, USA) was incubated during 1.5 h at room temperature.

    Techniques: Expressing, Control

    Relative collagen type I (COL1) protein abundance in equine endometrial explants obtained from mares in the mid-luteal phase (MLP; n = 5) and treated for 24 ( A ) or 48 h ( B ) with medium alone (control), transforming growth factor β1 (TGF-β1; 10 ng/mL), TGF-β1 (10ng/mL) + progesterone (P4; 10 − 7 M) or P4 (10 − 7 M), respectively. Results were analyzed by one-way analysis of variance (ANOVA), followed by a Tukey’s multiple comparisons test and considered significant at p < 0.05 and shown as mean ± SEM. Asterisks represent significant differences relative to the respective control and asterisks above lines designate differences between treatments (* p < 0.05; *** P < 0.001).

    Journal: Scientific Reports

    Article Title: Ovarian steroids modulate mRNA expression of ECM associated genes and collagen deposition induced by TGF β1 in equine endometrium in vitro

    doi: 10.1038/s41598-024-84250-1

    Figure Lengend Snippet: Relative collagen type I (COL1) protein abundance in equine endometrial explants obtained from mares in the mid-luteal phase (MLP; n = 5) and treated for 24 ( A ) or 48 h ( B ) with medium alone (control), transforming growth factor β1 (TGF-β1; 10 ng/mL), TGF-β1 (10ng/mL) + progesterone (P4; 10 − 7 M) or P4 (10 − 7 M), respectively. Results were analyzed by one-way analysis of variance (ANOVA), followed by a Tukey’s multiple comparisons test and considered significant at p < 0.05 and shown as mean ± SEM. Asterisks represent significant differences relative to the respective control and asterisks above lines designate differences between treatments (* p < 0.05; *** P < 0.001).

    Article Snippet: The primary antibody against COL1 (1:1000 diluted; RRID: AB_2891017, 20121, Novotec, Lyon, France) was incubated overnight at 4ºC, and the secondary antibody horseradish peroxidase (HRP)-conjugated anti-rabbit (1:20,000; RRID: AB_2617138; P0448, DakoCytomation, Carpinteria, CA, USA) was incubated during 1.5 h at room temperature.

    Techniques: Control

    In vitro and in vivo biocompatibility and osseointegration evaluation of the functionalized titanium screws. A,B) Representative western blot images of the expression of osteogenesis‐related proteins and C,D) corresponding quantitative analyses ( n = 3). E) Immunofluorescence images of RUNX2 and COL1 staining of MEFs in different groups. F) Schematic diagram of the osseointegration and biocompatibility test of functionalized screws in an uninfected bone defect model. G) The implantation process of functionalized screws in rabbit tibial plateau. H) The micro‐CT 3D reconstructed images and I) bone tissue volume/total tissue volume (BV/TV) analysis from micro‐CT results of the newly formed bone surrounding the screws after 56 days of implantation ( n = 3). J) The methylene blue‐basic magenta staining and corresponding K) bone‐implant contact (BIC) ratio analysis of the non‐decalcified bone sections for osseointegration assay ( n = 3). Green arrows indicate gaps between the screw and bone tissue. Blue arrows indicate bone‐implant contact areas. In I,J), The data are shown as the means ± SDs, * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Advanced Healthcare Materials

    Article Title: Efficacy of pH‐Responsive Surface Functionalized Titanium Screws in Treating Implant‐associated S. aureus Osteomyelitis with Biofilms Formation

    doi: 10.1002/adhm.202403261

    Figure Lengend Snippet: In vitro and in vivo biocompatibility and osseointegration evaluation of the functionalized titanium screws. A,B) Representative western blot images of the expression of osteogenesis‐related proteins and C,D) corresponding quantitative analyses ( n = 3). E) Immunofluorescence images of RUNX2 and COL1 staining of MEFs in different groups. F) Schematic diagram of the osseointegration and biocompatibility test of functionalized screws in an uninfected bone defect model. G) The implantation process of functionalized screws in rabbit tibial plateau. H) The micro‐CT 3D reconstructed images and I) bone tissue volume/total tissue volume (BV/TV) analysis from micro‐CT results of the newly formed bone surrounding the screws after 56 days of implantation ( n = 3). J) The methylene blue‐basic magenta staining and corresponding K) bone‐implant contact (BIC) ratio analysis of the non‐decalcified bone sections for osseointegration assay ( n = 3). Green arrows indicate gaps between the screw and bone tissue. Blue arrows indicate bone‐implant contact areas. In I,J), The data are shown as the means ± SDs, * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: Additionally, the MEFs treated as described above were fixed with 4% polyformaldehyde for 15 min and permeabilized with 0.1% Triton‐X for 15 min. After incubated with primary antibody RUNX2 (Abmart, dilution 1:500) or COL1 (Abmart, dilution 1:500) at 4 °C overnight, the MEFs were exposed to secondary antibody (Servicebio, dilution 1:500) for one hour at room temperature.

    Techniques: In Vitro, In Vivo, Western Blot, Expressing, Immunofluorescence, Staining, Micro-CT

    WAC was up‐regulated during the osteogenic differentiation of MSCs. a) ARS Staining and quantification throughout MSC osteogenic differentiation; b) ALP Staining and quantification during the progression of MSC osteogenesis; c) Immunofluorescence Staining for COL1 (red) during osteogenic induction. Quantification is presented in the right panel (Scale bar = 50 µm); d) Relative mRNA levels of WAC assessed by qRT‐PCR at different time points during MSC osteogenesis; e) Protein levels of WAC and osteogenic markers (RUNX2, Osterix, OCN) during MSC osteogenic differentiation; f) Pearson correlation analysis depicting the relationship between WAC expression and quantification of RUNX2, Osterix, and OCN levels during MSC osteogenic differentiation; g) qRT–PCR and Western blotting to detect WAC mRNA and protein levels in bone marrow MSCs from nonosteoporotic patients and patients with osteoporosis; h) HE staining and immunohistochemical staining for WAC in the femurs of SAMR1 mice and SAMP6 mice (Scale bar = 100 µm). All data are presented as the means ± SD, n = 6 per group in (a, b, c), n = 5 in (g), n = 9 in (d, e, g), n = 12 in (f). Statistical differences were determined using Student's t ‐test or ANOVA. ** p < 0.01 and *** p < 0.001.

    Journal: Advanced Science

    Article Title: WAC Facilitates Mitophagy‐mediated MSC Osteogenesis and New Bone Formation via Protecting PINK1 from Ubiquitination‐Dependent Degradation

    doi: 10.1002/advs.202404107

    Figure Lengend Snippet: WAC was up‐regulated during the osteogenic differentiation of MSCs. a) ARS Staining and quantification throughout MSC osteogenic differentiation; b) ALP Staining and quantification during the progression of MSC osteogenesis; c) Immunofluorescence Staining for COL1 (red) during osteogenic induction. Quantification is presented in the right panel (Scale bar = 50 µm); d) Relative mRNA levels of WAC assessed by qRT‐PCR at different time points during MSC osteogenesis; e) Protein levels of WAC and osteogenic markers (RUNX2, Osterix, OCN) during MSC osteogenic differentiation; f) Pearson correlation analysis depicting the relationship between WAC expression and quantification of RUNX2, Osterix, and OCN levels during MSC osteogenic differentiation; g) qRT–PCR and Western blotting to detect WAC mRNA and protein levels in bone marrow MSCs from nonosteoporotic patients and patients with osteoporosis; h) HE staining and immunohistochemical staining for WAC in the femurs of SAMR1 mice and SAMP6 mice (Scale bar = 100 µm). All data are presented as the means ± SD, n = 6 per group in (a, b, c), n = 5 in (g), n = 9 in (d, e, g), n = 12 in (f). Statistical differences were determined using Student's t ‐test or ANOVA. ** p < 0.01 and *** p < 0.001.

    Article Snippet: Subsequently, the cells were treated with Triton X‐100 for 15 min at room temperature and incubated with goat serum for 30 min. Primary antibodies against COL1 (Cell Signaling Technology, Cat. No. 66 948), LC3B (Abcam, Cat. No. Ab192890), or TOM20 (Abcam, Cat. No. Ab186735) were added and left to incubate overnight at 4 °C.

    Techniques: Staining, Immunofluorescence, Quantitative RT-PCR, Expressing, Western Blot, Immunohistochemical staining

    WAC positively regulated the osteogenic differentiation of MSCs in vitro. WAC is modulated in MSCs through SiRNA and Lentivirus. a) MSCs were cultured in osteogenic medium after transfection with SiRNA. ARS staining, ALP staining, and quantification were performed on day 12; b) Western blotting for protein levels of osteogenesis‐related markers (RUNX2, Osterix, OCN). Quantification is presented in the right panel; c) Immunofluorescence staining for COL1 (red) after SiRNA transfection. Quantification is shown in the right panel (Scale bar = 50 µm); d) Overexpression lentivirus of WAC transfected into MSCs, followed by culture in osteogenic medium. ARS staining, ALP staining, and quantification conducted on day 12; e) Western blotting for protein levels of osteogenesis‐related markers after overexpression lentivirus transfection; f) Immunofluorescence staining for COL1 (red) after overexpression lentivirus transfection. Quantification is shown in the right panel (Scale bar = 50 µm). All data are presented as the means ± SD, n = 6 per group in (a, c, d, f), n = 9 per group in (b, e). Statistical differences were determined using Student's t ‐test or ANOVA. ns not statistically significant, ** p < 0.01 and *** p < 0.001.

    Journal: Advanced Science

    Article Title: WAC Facilitates Mitophagy‐mediated MSC Osteogenesis and New Bone Formation via Protecting PINK1 from Ubiquitination‐Dependent Degradation

    doi: 10.1002/advs.202404107

    Figure Lengend Snippet: WAC positively regulated the osteogenic differentiation of MSCs in vitro. WAC is modulated in MSCs through SiRNA and Lentivirus. a) MSCs were cultured in osteogenic medium after transfection with SiRNA. ARS staining, ALP staining, and quantification were performed on day 12; b) Western blotting for protein levels of osteogenesis‐related markers (RUNX2, Osterix, OCN). Quantification is presented in the right panel; c) Immunofluorescence staining for COL1 (red) after SiRNA transfection. Quantification is shown in the right panel (Scale bar = 50 µm); d) Overexpression lentivirus of WAC transfected into MSCs, followed by culture in osteogenic medium. ARS staining, ALP staining, and quantification conducted on day 12; e) Western blotting for protein levels of osteogenesis‐related markers after overexpression lentivirus transfection; f) Immunofluorescence staining for COL1 (red) after overexpression lentivirus transfection. Quantification is shown in the right panel (Scale bar = 50 µm). All data are presented as the means ± SD, n = 6 per group in (a, c, d, f), n = 9 per group in (b, e). Statistical differences were determined using Student's t ‐test or ANOVA. ns not statistically significant, ** p < 0.01 and *** p < 0.001.

    Article Snippet: Subsequently, the cells were treated with Triton X‐100 for 15 min at room temperature and incubated with goat serum for 30 min. Primary antibodies against COL1 (Cell Signaling Technology, Cat. No. 66 948), LC3B (Abcam, Cat. No. Ab192890), or TOM20 (Abcam, Cat. No. Ab186735) were added and left to incubate overnight at 4 °C.

    Techniques: In Vitro, Cell Culture, Transfection, Staining, Western Blot, Immunofluorescence, Over Expression